A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients

Inclusion Criteria: * Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures * Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living kidney transplant * Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure * Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization Exclusion Criteria: * Patient has previously received or is receiving an organ transplant other than a kidney * Patient has received a kidney transplant from a non-heart beating donor * Patient has received an ABO incompatible donor kidney * Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV) * Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully * Patient has significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site * Patient has an uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives * Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant * Patient is receiving everolimus or enteric coated mycophenolic acid at any time during the study * Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or corticosteroids * Patient is pregnant or lactating * Patient is unlikely to comply with the visits scheduled in the protocol * Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator